Conditions for the achievement of pharmaceutical innovation for sustainable development: lessons from India

摘要

This paper shows the post-TRIPS experience to be contradicting the overstated claim that "the adverse effect of TRIPS Agreement on prices of patented medicines would be adequately compensated by the benefits of technology transfer and domestic R&D". It argues that policymakers cannot continue to formulate their strategic interventions with an understanding that "strong IPRs are going to help define the pharmaceutical knowledge markets to be competitive and favourable for the development of people oriented innovations". Strategic interventions of the government should make the pharmaceutical sector to work for the benefit of therapies needed by the people of India and LDCs.